Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure

Vodovar, Nicolas; Seronde, Marie‐France; Laribi, Sai͏̈d; Gayat, Étienne; Lassus, Johan; Boukef, Riadh; Nouira, Semir; Manivet, Philippe; Samuel, Jane‐Lise; Logeart, Damien; Ishihara, Shiro; Solal, Alain Cohen; Januzzi, James L.; Richards, A. Mark; Launay, Jean‐Marie; Mebazaa, Alexandre

doi:10.1093/eurheartj/ehu314

Cited by 99 publications

(61 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The highest percentage of glycosylated proBNP is present in patients with chronic HF compared to patients in the acute decompensated and nonacute decompensated groups (30 ). Another interesting finding is that furin activity but not its concentration is greater in the acute HF group than in the chronic HF group (30 ).…”

Section: Probnp Circulating Forms In Acute and Chronic Hfmentioning

confidence: 93%

“…Another interesting finding is that furin activity but not its concentration is greater in the acute HF group than in the chronic HF group (30 ). Perhaps there is a differential mechanism of proBNP processing in disease progression in HF patients with increased BNP production in the acute decompensated group of patients with fluid overload.…”

Section: Probnp Circulating Forms In Acute and Chronic Hfmentioning

confidence: 95%

“…While the first generation of NT-proBNP immunoassays uses polyclonal antibodies to amino acids 1-21 and 39 -50, the second generation uses monoclonal antibodies (MAb) recognizing the central region of NTproBNP: amino acids 22-28 and 42-46 (27)(28)(29)(30)(31). Many studies have demonstrated the negative effect of glycosylation for antibody recognition to the middle area of the NT-proBNP molecule.…”

Section: Nt-probnp Assaysmentioning

confidence: 99%

See 2 more Smart Citations

Natriuretic Peptides and Analytical Barriers

Vasile

Jaffe

2017

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND:The natriuretic peptide system is an endocrine, autocrine and paracrine system that plays an important role in the maintenance of cardiovascular homeostasis. Biomarkers based on these peptides are important diagnostic and prognostic tools for myocardial function.CONTENT: Although natriuretic peptides were discovered more than 2 decades ago, their intricate and complex biology is associated with important questions not yet elucidated. The diversity of circulating forms of natriuretic peptides, the distinct expression of these forms in particular patients, and the heterogeneity of heart failure forms, along with specific assay-related and preanalytic issues, cause assays to be poorly harmonized.

show abstract

Section: Probnp Circulating Forms In Acute and Chronic Hfmentioning

confidence: 93%

Section: Probnp Circulating Forms In Acute and Chronic Hfmentioning

confidence: 95%

Section: Nt-probnp Assaysmentioning

confidence: 99%

See 1 more Smart Citation

Natriuretic Peptides and Analytical Barriers

Vasile

Jaffe

2017

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

“…There are good data to suggest that NP role as a screening tool for Stage B could be altered by the metabolic status of the diabetic patient, Insulin levels, obesity (Khan et al, 2011, Wang et al, 2004, Sugisawa et al, 2010 and the impact of glycosylation on NP processing and detection may all play a role (Semenov et al, 2010, Semenov et al, 2009, Vodovar et al, 2014. Clarification of the interaction between NP and diabetes is essential if we are to effectively apply this peptide in a screening process.…”

Section: Introductionmentioning

confidence: 99%

Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure

et al. 2016

View full text Add to dashboard Cite

Abstract:Context Natriuretic peptide (NP) has been shown to be an effective screening tool to identify patients with Stage B heart failure and to have clinical value in preventing heart failure progression . The impact of associated metabolic confounders on the screening utility of NP needs clarification. ObjectiveTo assess the impact of diabetes (DM) on NP screening for asymptomatic Stage B heart failure. Materials and MethodsThe study population consisted of 1368 asymptomatic patients with cardiovascular risk factors recruited from general practice as part of the STOP-HF trial. B-type NP (BNP) was quantified at pointof-care. ResultsBNP was found to be as accurate for detecting Stage B heart failure in DM patients compared to non-DM patients (AUC 0.75 [0.71,0.78] and 0.77 [0.72,0.82], respectively). However, different BNP thresholds are required to achieve the same level of diagnostic sensitivity in DM compared with non-DM patients. To achieve 80% sensitivity a difference of 5ng/L lower is required for patients with diabetes. ConclusionAlthough a significantly different BNP threshold is detected for patients with DM, the BNP concentration difference is small and unlikely to warrant a clinically different diagnostic threshold.3 Background:

show abstract

“…В конечном счете, это приводит к увеличению диуреза и натрийурезу [27]. Последние данные позволяют предположить, что, помимо высвобождения пептида, миокардиальный стресс вызывает каскад реакций, увеличивающих дегликозилирование BNP и продукцию фурина, одного из основных ферментов для преобразования пропептида и его N-концевой фракции в активную форму, тем самым способствуя более быстрому био-логическому действию [28].…”

Section: патофизиология острой сердечной недостаточности что нового?unclassified